Sljedeći

Auto Play

Peptide Receptor Radionuclide Therapy (PRRT)

3 Pogledi • 07/09/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play